These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 17968685

  • 1. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V, Seldin DC.
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [Abstract] [Full Text] [Related]

  • 2. Primary amyloidosis of the kidney.
    Shafique S, Wetmore J, Almehmi A.
    W V Med J; 2010 Dec; 106(1):22-4. PubMed ID: 20088306
    [Abstract] [Full Text] [Related]

  • 3. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [Abstract] [Full Text] [Related]

  • 4. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lachmann HJ, Wechalekar AD, Gillmore JD.
    N Engl J Med; 2008 Jan 03; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
    [No Abstract] [Full Text] [Related]

  • 5. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F.
    Arch Cardiovasc Dis; 2008 Sep 03; 101(9):523-32. PubMed ID: 19041836
    [Abstract] [Full Text] [Related]

  • 6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.
    Am J Kidney Dis; 2005 Aug 03; 46(2):270-7. PubMed ID: 16112045
    [Abstract] [Full Text] [Related]

  • 7. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lokhorst HM, Hazenberg BP, Croockewit A.
    N Engl J Med; 2008 Jan 03; 358(1):92; author reply 92-3. PubMed ID: 18172953
    [No Abstract] [Full Text] [Related]

  • 8. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Mehta J.
    N Engl J Med; 2008 Jan 03; 358(1):91; author reply 92-3. PubMed ID: 18175385
    [No Abstract] [Full Text] [Related]

  • 9. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T, Ogata M, Kohno K, Tomo T, Ohtsuka E, Kikuchi H, Kadota J.
    Am J Hematol; 2006 Apr 03; 81(4):281-3. PubMed ID: 16550508
    [Abstract] [Full Text] [Related]

  • 10. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Comenzo RL, Steingart RM, Cohen AD.
    N Engl J Med; 2008 Jan 03; 358(1):92; author reply 92-3. PubMed ID: 18175384
    [No Abstract] [Full Text] [Related]

  • 11. Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation.
    Katoh N, Matsuda M, Yoshida T, Yazaki M, Morita H, Sakashita K, Ikeda S.
    Muscle Nerve; 2010 Jan 03; 41(1):138-43. PubMed ID: 19813189
    [Abstract] [Full Text] [Related]

  • 12. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Kumar S, Dispenzieri A, Gertz MA.
    N Engl J Med; 2008 Jan 03; 358(1):91; author reply 92-3. PubMed ID: 18172183
    [No Abstract] [Full Text] [Related]

  • 13. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
    Charlinski G, Ziarkiewicz M, Boguradzki P, Wiater E, Torosian T, Dwilewicz-Trojaczek J, Wiktor-Jedrzejczak W.
    Transplant Proc; 2014 Oct 03; 46(8):2877-81. PubMed ID: 25380940
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA, Sonneveld P, de Man RA, Leebeek FW.
    Eur J Haematol; 2004 Mar 03; 72(3):181-5. PubMed ID: 14962236
    [Abstract] [Full Text] [Related]

  • 15. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
    Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.
    Transpl Infect Dis; 2013 Apr 03; 15(2):187-94. PubMed ID: 23279695
    [Abstract] [Full Text] [Related]

  • 16. Modern treatment of amyloidosis: unresolved questions.
    Dember LM.
    J Am Soc Nephrol; 2009 Mar 03; 20(3):469-72. PubMed ID: 19073820
    [Abstract] [Full Text] [Related]

  • 17. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis.
    Snanoudj R, Mamzer-Bruneel MF, Hermine O, Grunfeld JP, Chauveau D.
    Nephrol Dial Transplant; 2003 Oct 03; 18(10):2175-7. PubMed ID: 13679499
    [No Abstract] [Full Text] [Related]

  • 18. [A case of primary amyloidosis].
    Ardashev VN, Potekhin NP, Rukavitsyn OA, Borisov AG, Malysheva SA.
    Klin Med (Mosk); 2006 Oct 03; 84(6):56-9. PubMed ID: 16875072
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.
    Ann Hematol; 2009 Jul 03; 88(7):681-5. PubMed ID: 19066891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.